Xencor Announced Sunday At ESMO, Phase 1 XmAb819 Data In Advanced Clear Cell Renal Cell Carcinoma Showing 45.5% Confirmed ORR
Share
Why It Matters
Xencor showed early test results for a new cancer medicine. Doctors watch early results to see if the medicine might help patients down the road.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.